How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

September 20, 2013

Absorbing the Cost of Personalized Medicine

Matthew Palmgren discusses the benefits of personalized medicines

October 14, 2014

Useful Patient Tools Available for Patients with Polycythemia Vera

Dr. Michaelis discusses useful tools in her experience for treatment of polycthemia vera.Supported through funding from Incyte